Daunorubicin injection
Products billed under this code include Daunorubicin HCl.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Daunorubicin HCl.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Daunorubicin HCl | Hikma Pharmaceuticals USA Inc. | 00143-9550-01 | 5 | $134.56 |
| Daunorubicin HCl | Hikma Pharmaceuticals USA Inc. | 00143-9551-10 | 20 | $538.24 |
| Daunorubicin HCl | Hisun Pharmaceuticals USA, Inc | 42658-0021-01 | 2 | $53.824 |
| Daunorubicin HCl | Hisun Pharmaceuticals USA, Inc | 42658-0021-02 | 20 | $538.24 |
| Daunorubicin HCl | Hisun Pharmaceuticals USA, Inc | 42658-0021-91 | 2 | $53.824 |
| Daunorubicin HCl | Hisun Pharmaceuticals USA, Inc | 42658-0021-92 | 20 | $538.24 |
| Daunorubicin HCl | Meitheal Pharmaceuticals Inc. | 71288-0182-05 | 20 | $538.24 |
| Daunorubicin Hcl | Hisun Pharmaceuticals USA, Inc | 42658-0019-01 | 5 | $134.56 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $26.912 | −$1.898 | 10 MG | Daunorubicin injection | v1, posted September 17, 2026 |
| 3Q26 | $28.81 | +$4.062 | 10 MG | Daunorubicin injection | v1, posted September 15, 2026 |
| 2Q26 | $24.748 | −$1.578 | 10 MG | Daunorubicin injection | v1, posted September 15, 2026 |
| 1Q26 | $26.326 | +$4.627 | 10 MG | Daunorubicin injection | v1, posted September 15, 2026 |
| 4Q25 | $21.699 | +$1.937 | 10 MG | Daunorubicin injection | v1, posted September 8, 2026 |
| 3Q25 | $19.762 | −$6.635 | 10 MG | Daunorubicin injection | v1, posted March 10, 2026 |
| 2Q25 | $26.397 | +$2.88 | 10 MG | Daunorubicin injection | v1, posted March 10, 2026 |
| 1Q25 | $23.517 | −$0.919 | 10 MG | Daunorubicin injection | v1, posted December 19, 2025 |
| 4Q24 | $24.436 | −$2.227 | 10 MG | Daunorubicin injection | v1, posted June 11, 2025 |
| 3Q24 | $26.663 | −$4.841 | 10 MG | Daunorubicin injection | v1, posted June 11, 2025 |
| 2Q24 | $31.504 | −$4.167 | 10 MG | Daunorubicin injection | v1, posted March 11, 2025 |
| 1Q24 | $35.671 | +$4.035 | 10 MG | Daunorubicin injection | v1, posted December 19, 2024 |
| 4Q23 | $31.636 | −$13.986 | 10 MG | Daunorubicin injection | v1, posted October 10, 2024 |
| 3Q23 | $45.622 | +$8.459 | 10 MG | Daunorubicin injection | v1, posted June 5, 2024 |
| 2Q23 | $37.163 | −$4.481 | 10 MG | Daunorubicin injection | v1, posted February 23, 2024 |
| 1Q23 | $41.644 | −$4.909 | 10 MG | Daunorubicin injection | v1, posted December 6, 2023 |
| 4Q22 | $46.553 | +$2.508 | 10 MG | Daunorubicin injection | v1, posted June 22, 2023 |
| 3Q22 | $44.045 | +$4.468 | 10 MG | Daunorubicin injection | v1, posted June 9, 2023 |
| 2Q22 | $39.577 | −$1.659 | 10 MG | Daunorubicin injection | v1, posted December 14, 2022 |
| 1Q22 | $41.236 | +$0.88 | 10 MG | Daunorubicin injection | v1, posted June 8, 2022 |
| 4Q21 | $40.356 | −$4.886 | 10 MG | Daunorubicin injection | v1, posted June 2, 2022 |
| 3Q21 | $45.242 | +$2.876 | 10 MG | Daunorubicin injection | v1, posted June 2, 2022 |
| 2Q21 | $42.366 | −$0.154 | 10 MG | Daunorubicin injection | v1, posted March 1, 2022 |
| 1Q21 | $42.52 | – | 10 MG | Daunorubicin injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.